Health Care & Hospital Law
Aug. 12, 2010
Patients Push for Fabry Drug Fix
Patients who take an enzyme replacement therapy the reduces the symptoms of the genetic disorder want the government to use a seldom-used law to wrest exclusive rights away from Genzyme Corp.
Daily Journal Staff Writer
Only one drug approved in the United States prevents the symptoms of Fabry disease.
That's why patients who take Fabrazyme, an enzyme replacement therapy that reduces the symptoms of the genetic disorder, want the government to invoke a seldom-used law to wrest exclusive rights away from Genzyme Corp., to increase production of the scarce and costly drug it originally brought to t...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$895, but save $100 when you subscribe today… Just $795 for the first year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In